MODEL SYSTEMS

MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice

Nacho Aguiloa, b, 1, Santiago Uranga a, b, Dessislava Marinova a, b, Marta Monzon c, Juan Badiola c, Carlos Martin a, b, d, *1

a Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, 50009 Zaragoza, Spain
b CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
c Research Centre for Encephalopathies and Transmissible Emerging Diseases, Universidad de Zaragoza, 50013 Zaragoza, Spain
d Servicio de Microbiología, Hospital Universitario Miguel Servet, IES Aragón, 50009 Zaragoza, Spain

A R T I C L E I N F O

Article history:
Received 4 September 2015
Received in revised form
22 October 2015
Accepted 23 October 2015

Keywords:
MTBVAC
Newborn mice
Tuberculosis vaccine
Neonates

S U M M A R Y

Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a mouse model of newborn mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Tuberculosis (TB) disease causes more than one million and a half deaths per year and is one of the leading infectious diseases affecting developing countries. Thus, development of new vaccines able to prevent TB represents a global emergency [1].

The only vaccine against TB in use today, Bacille Calmette-Guerin (BCG), is a live attenuated strain from a Mycobacterium bovis strain isolated from cattle, and is worldwide administered at birth. Despite its effectiveness in reducing the incidence of the disseminated forms of TB in children, it is inconsistent in preventing pulmonary TB, the most common form of the disease in adolescents and adults, and responsible of TB transmission [2]. BCG was developed a century ago by repeated subculture. The loss of the RD1 region-the principal genetic basis for its attenuation-, encodes a secretion system to export the major T-cell antigen complex/ virulence factor ESAT-6/CFP-10 [3]. In addition, when compared to clinical isolates of the Mycobacterium tuberculosis complex, BCG has more than one hundred genes deleted from its genome [4], including important immunodominant antigen proteins which contain a high proportion of epitopes recognized by HLA complex, considered important in generating effective long-lasting immune responses [5]. Some of these antigens are employed in different subunit TB vaccines for use in BCG-vaccinated individuals, currently in clinical trials [1].

MTBVAC is a live rationally-attenuated derivative of the M. tuberculosis isolate MT103, which belongs to the Lineage 4 (Euro-American), one of the most widespread lineages of M. tuberculosis [6]. MTBVAC contains two independent stable deletion mutations in the virulence genes phoP and fadD26 without antibiotic resistance marker, in accordance to the established in the Second Geneva Consensus document for progressing new live mycobacterial vaccines to advanced clinical development [7]. PhoP is a transcription factor that controls 2% of the genome of MTB including production of immunomodulatory cell-wall lipids and ESAT-6 secretion [8]. Deletion of fadD26 leads to complete synthesis abrogation of the virulence surface lipids phthioceroldimycocerosates (DIM) [9]. MTBVAC has been the first and only live attenuated M. tuberculosis vaccine approved to enter into clinical trials. A first-in-human

http://dx.doi.org/10.1016/j.tube.2015.10.010
1472-9792/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
MTBVAC clinical trial was recently conducted successfully in healthy adults in Lausanne (Switzerland) (NCT02013245) [10].

Newborn mice have been used in different works as a model to measure safety, immunogenicity and protective efficacy of BCG alone or in combination with diverse boosting approaches [11]. Given that the preclinical development of MTBVAC to date was generated in adult animal models with the objective to support the first-in-human adult Phase 1a safety and immunogenicity trial in Lausanne, the present safety and immunogenicity study in newborn mice is the first to date conducted to support progress to Phase 1b evaluation of MTBVAC in newborns.

2. Material and methods

All mice were kept under controlled conditions and observed for any sign of disease. Experimental work was conducted in agreement with European and national directives for protection of experimental animals and with approval from the competent local ethics committees.

For vaccination with lyophilized BCG Danish 1331 (Statens Serum Institute SSI) or MTBVAC (manufactured by Biofabri, Spain), approximately $5 \times 10^8$ colony-forming units (CFU) were reconstituted with 1 mL of reconstitution buffer. Groups of C57/BL6 newborn mice were vaccinated subcutaneously with 50 μl of reconstituted vaccines ($2.5 \times 10^5$ CFU) in the first three days of birth. Unvaccinated controls were inoculated with 50 μl of phosphate buffered saline (PBS).

2.1. Safety

During the next eight weeks following vaccination of the newborn mice, different welfare-related parameters as weight gain, social and individual behaviour and food and water consumption were monitored. Eight weeks post-vaccination, animals were sacrificed and the target organs (spleen, kidneys, testes, ovaries, heart, lungs, liver and brain) were harvested, weighed and fixed in formaldehyde for haematoxylin-eosin staining and pathological evaluation. The experts in charge of the anatomopathological examination were blinded to the vaccine group origin of the indicated organs.

2.2. Immunogenicity

For immunogenicity assessment, $10^6$ splenocytes per experimental point were incubated with purified-protein derivative (PPD) (Statens Serum Institut SSI) 10 μg/ml or recombinant Ag85B (Lionex) 2 μg/ml in culture medium during 48 h. After incubation, supernatant was separated from the cellular fraction by centrifugation and IFNγ concentration determined by ELISA using a specific commercial kit (MabTech), and performed according to manufacturer instructions.

2.3. Protective efficacy

Eight weeks post-vaccination, mice were intranasally challenged with 150 CFU MTB H37Rv in 40 μl of PBS. Bacterial load from lungs was determined four weeks post—challenge by plating lung homogenates on solid 7H11 agar medium supplemented with ADC (Difco).

2.4. Statistical analysis

GraphPrism software was used for statistical analysis. For experiments with two experimental groups, unpaired t-student test was used. When three or more groups were compared, One-Way ANOVA analysis with Bonferroni post-test was performed. Differences were considered significant at $p < 0.05$.

3. Results and discussion

Despite the failure of the subunit vaccine MVA85A to improve BCG efficacy in an infant Phase 2b trial in South Africa, the clinical trial paved the way for testing of new TB vaccines in infants [12]. Some authors have criticized that considering the MVA85A preclinical data available the failure of this vaccine candidate was not unexpected [13,14]. Thus a lesson to be learnt through the experience with MVA85A is the necessity to conduct rigorous preclinical characterization of vaccine candidates in models mimicking as much as possible the conditions planned for testing in the clinic. Since MTBVAC was conceived as a BCG-replacement strategy, newborns represent its main target population. Nevertheless, all the preclinical studies performed up to date with MTBVAC, or its prototype version SO2 [7], have been carried out in different adult animal models, showing an excellent safety profile in all preclinical experiments performed [7,15]. Following the successful outcome of the first-in-human Phase 1a trial in healthy adults in Lausanne, we conducted the present study of MTBVAC in a neonatal preclinical model with the aim to support progress to clinical evaluation in healthy newborn infants.

3.1. Safety evaluation

In the whole study, a total of 80 newborn mice were vaccinated with MTBVAC with no mortality or disease-associated symptomatology. As shown in Figure 1, both male and female mice vaccinated with MTBVAC gained weight in a similar way when compared to control BCG and unvaccinated groups. At eight weeks post—birth, animals were euthanatized and pivotal organs were harvested for further analysis. No significant differences with respect to organ weight were found in any of the organs studied (Supplementary Table 1). In addition, an anatomopathological blind analysis from the selected organs was performed. Our results
show no histopathological differences related to vaccination in any of the studied organs. Thus, we conclude that MTBVAC did not produce structural or developmental changes in any studied organ in newborn immunized mice.

3.2. Immunogenicity evaluation

Newborn immunization takes place when the immune system is still immature which may represent an important difference to vaccination in adults. This fact could have an impact in the immune response triggered by vaccination. Indeed, Phase 2b and other MVA85A clinical studies have shown that Th1 responses induced by this vaccine are weaker in infants compared to adults [12]. To assess vaccine-induced immunogenicity with MTBVAC, we harvested splenocytes from eight-week-old mice vaccinated at birth and stimulated ex vivo cells with PPD (Figure 2A) or single antigen Ag85B (Figure 2B) for 48 h. We analysed next IFNγ production by ELISA. IFNγ production was higher in the group of MTBVAC-vaccinated mice after stimulation with PPD or Ag85B. PPD results contrasted with those obtained in adult C57/BL6 mice, where non-significant differences between MTBVAC- and BCG-vaccinated animals were found after PPD stimulation ([16], Unpublished results).

Figure 2. Immunogenicity conferred by vaccination at birth in C57/BL6 mice. Groups of six newborn C57/BL6 mice were vaccinated with MTBVAC, BCG or PBS. Immunogenicity was studied at eight weeks post-birth. Animals were humanely sacrificed and a cellular suspension from spleen was obtained. Cells were stimulated with PPD (A) or Ag85B (B) for 48 h and subsequently IFNγ analysed in cell supernatant by ELISA. A representative experiment of two is shown. Data in the graphs are represented as mean ± SEM. One-way ANOVA test with Bonferroni post analysis was performed to calculate statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001.

Figure 3. Protective efficacy conferred by vaccination at birth in C57/BL6 mice. Groups of three to nine newborn C57/BL6 mice were vaccinated with MTBVAC, BCG or PBS. At eight weeks post-birth, animals were challenged intranasally with H37Rv and four weeks later CFUs were determined in lungs (A) and spleen (B). Data of two independent experiments are shown in the figure. Data in the graphs are represented as mean ± SEM. One-way ANOVA test with Bonferroni post analysis was performed to calculate statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. P value shown in Experiment 2 (SPLPEN) graph, comparing BCG and MTBVAC groups, was determined using a Mann–Whitney t-student test.
The results with Ag85B may be relevant, based on data with other Ag85B-based vaccines showing improved protective efficacy when compared to BCG, suggesting that Ag85B-specific response could be protective [17]. Ag85B is one of the most antigenic proteins of *M. tuberculosis*, harbouring a number of experimentally confirmed human T cell epitopes. Importantly, a recent report showed that all BCG strains contain a polymorphism in ag85b gene, which triggers an amino acid substitution predicted to affect protein’s structure and stability [5].

### 3.3. Protective efficacy evaluation

To evaluate protective efficacy, we intranasally inoculated eight-week old mice vaccinated at birth with a low dose of H37Rv and four weeks after challenge we determined bacterial load reduction in lungs and spleen. A group of ten unvaccinated mice was sacrificed one day after challenge to determine the initial number of bacteria in lungs, resulting in a mean value ± SEM of 29 CFU ± 11. The two independent experiments performed showed a similar efficacy profile in lungs and spleen, and both BCG and MTBVAC conferred significant protection in comparison with unvaccinated controls. Remarkably, bacterial reduction in lungs induced by MTBVAC was significantly higher (around 0.5 logs) than the decrease triggered by BCG. In the case of bacterial load in spleen, MTBVAC also tended to provide a better protection than BCG, although no significance was observed in this case (Figure 3).

Since BCG is effective in preventing disseminated TB in children one of the potential issues of BCG-replacement TB vaccines is that individuals in TB-endemic countries not vaccinated with BCG at birth might be at risk of developing disseminated TB in childhood. Given that MTBVAC is aimed for use at birth, our data provide evidence for the adequate safety and improved immunogenicity and protection efficacy profile as compared to licensed BCG Danish SSI, suggesting that newborn vaccination with MTBVAC in clinic is expected to be at least as safe, immunogenic and effective as BCG.

### 4. Conclusions

The most important conclusion of this study is that MTBVAC is safe in newborn mice, and does not affect organ development. To our knowledge, this is the first time that a live attenuated *M. tuberculosis* vaccine is tested in a preclinical neonatal model, so this work can pave the way for the preclinical and clinical development of other *M. tuberculosis*-based vaccines targeting this population.

### Acknowledgements

The authors gratefully acknowledge Biofabri and Tuberculosis Vaccine Initiative (TBVI) Preclinical & Clinical Development Teams for their expertise and advise in the elaboration of the protocols for safety evaluation of MTBVAC in the mouse neonatal model.

### Funding

This work was supported by “Fundación Española de la Ciencia y la Tecnología” [grant INNOCASH (INC-098), “Spanish Ministry of Economy and Competitiveness” [grant numbers BIO2011-23555, BIO2014-5258P], “European Commission FP7 and H2020 programs” [grant numbers NEWTBVAC 241745, TBVAC2020 643381], and “Gobierno de Aragón/Fondo Social Europeo”. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

### Conflict of interest

Carlos Martin is co-inventor of the patent “tuberculosis vaccine” filled by the University of Zaragoza. There are no interests of conflict.

### Ethical approval

Experimental work was conducted in agreement with European and national directives for protection of experimental animals and with approval from the competent local ethics committees.

### Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.tube.2015.10.010.

### References